A phase II, multicenter, single-arm study of pemigatinib in patients with metastatic or unresectable colorectal cancer harboring FGFR alterations is a research paper published in The Oncologist (2025). On theSindex it has a DataRank of 0.232. It has been cited 3 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
0.0239
From 2 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 3 citers.
National Institutes of Health
Grant: 2T32CA217834-07
NCI NIH HHS
Grant: T32 CA217834
National Institutes of Health
Grant: 5P30CA068485-27
Cancer Center Support Grant
National Institutes of Health
Grant: 5T32CA217834-04
VIMORTP (Vanderbilt Integrated Molecular Oncology Research Training Program)
Fields of Study
MeSH Terms
Keywords